Atacicept in Multiple Glomerular Diseases
← catalyst calendarNCT06983028 · readout ≤ 468 d
Sponsored by Vera Therapeutics, Inc. (industry) · VERA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
250estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-07 | actual | When the study began enrolling |
| Primary completion | Nov 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- pMN
- IgAN
- Nephrotic Syndrome
- MCD
- FSGS
Intervention
- Drug: Atacicept
Primary outcomes
what the primary-completion date above is the date OFAE profile and results of routine clinical and laboratory tests
measured Baseline until end of study: 52 + 26 Weeks
Percent reduction in urine protein to creatinine ratio (UPCR)
measured Baseline, Week 36
Permalink · VERA's whole pipeline · Catalyst calendar · Every registered study · What changed